Oral Humira Biosimilar Could Be A Game-Changer, Says Rani CEO

Talat Imran Talks About Rani Therapeutics’ RaniPill Robotic Capsule For Biologics

 
• By Dave Wallace

Oral delivery of biosimilars could bring significant benefits for patients as well as offering a key differentiating factor for competing developers, especially in the US adalimumab arena, Rani Therapeutics CEO Talat Imran tells Generics Bulletin.

Talat Imran, Rani Therapeutics
Talat Imran sees significant advantages for oral delivery of biosimilars via robotic capsules • Source: Rani Therapeutics

More from Biosimilars

More from Products